Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CBMG NASDAQ:EIGR NASDAQ:IPHA OTCMKTS:IPHYF NASDAQ:OCGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBMGCellular Biomedicine Group$19.68$11.48▼$19.75$384.69M1.35129,776 shs8,375 shsEIGREiger BioPharmaceuticals$4.35$1.10▼$43.35$2.55M1.83103,866 shs137,800 shsIPHAInnate Pharma$2.07+3.3%$2.05$1.29▼$3.51$184.37M0.229,750 shs9,961 shsIPHYFInnate Pharma$2.00+23.5%$1.68$1.31▼$2.06$167.66M0.54,674 shs24,860 shsOCGNOcugen$1.20+12.1%$1.04$0.52▼$1.29$312.77M4.161.62 million shs10.97 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBMGCellular Biomedicine Group0.00%0.00%0.00%0.00%0.00%EIGREiger BioPharmaceuticals0.00%0.00%0.00%0.00%0.00%IPHAInnate Pharma+3.25%+1.23%-3.28%+10.43%-8.63%IPHYFInnate Pharma0.00%-2.89%-2.89%+15.27%-13.04%OCGNOcugen+12.15%+16.50%+14.29%+10.09%-0.83%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBMGCellular Biomedicine Group$19.68$11.48▼$19.75$384.69M1.35129,776 shs8,375 shsEIGREiger BioPharmaceuticals$4.35$1.10▼$43.35$2.55M1.83103,866 shs137,800 shsIPHAInnate Pharma$2.07+3.3%$2.05$1.29▼$3.51$184.37M0.229,750 shs9,961 shsIPHYFInnate Pharma$2.00+23.5%$1.68$1.31▼$2.06$167.66M0.54,674 shs24,860 shsOCGNOcugen$1.20+12.1%$1.04$0.52▼$1.29$312.77M4.161.62 million shs10.97 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBMGCellular Biomedicine Group0.00%0.00%0.00%0.00%0.00%EIGREiger BioPharmaceuticals0.00%0.00%0.00%0.00%0.00%IPHAInnate Pharma+3.25%+1.23%-3.28%+10.43%-8.63%IPHYFInnate Pharma0.00%-2.89%-2.89%+15.27%-13.04%OCGNOcugen+12.15%+16.50%+14.29%+10.09%-0.83%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBMGCellular Biomedicine Group 0.00N/AN/AN/AEIGREiger BioPharmaceuticals 0.00N/AN/AN/AIPHAInnate Pharma 3.33Buy$11.00432.69% UpsideIPHYFInnate Pharma 0.00N/AN/AN/AOCGNOcugen 3.00Buy$6.00400.00% UpsideCurrent Analyst Ratings BreakdownLatest CBMG, EIGR, OCGN, IPHYF, and IPHA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/4/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.007/28/2025IPHAInnate PharmaBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy6/24/2025OCGNOcugenHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.006/24/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBMGCellular Biomedicine Group$340K0.00N/AN/A$2.89 per share0.00EIGREiger BioPharmaceuticals$15.77M0.00N/AN/A$37.68 per share0.00IPHAInnate Pharma$21.77M8.74N/AN/A$0.11 per share18.77IPHYFInnate Pharma$21.77M7.70N/AN/A$0.11 per share18.18OCGNOcugen$4.05M86.61N/AN/A$0.10 per share12.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBMGCellular Biomedicine Group-$49.98MN/AN/AN/AN/AN/A-144.80%-61.68%N/AEIGREiger BioPharmaceuticals-$96.78M-$59.16N/AN/AN/A-590.80%-332.49%-99.77%N/AIPHAInnate Pharma-$53.53MN/A0.00∞N/AN/AN/AN/A9/17/2025 (Estimated)IPHYFInnate Pharma-$53.53MN/A0.00∞N/AN/AN/AN/A9/17/2025 (Estimated)OCGNOcugen-$54.05M-$0.20N/AN/AN/A-1,197.71%-255.25%-86.79%11/13/2025 (Estimated)Latest CBMG, EIGR, OCGN, IPHYF, and IPHA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/1/2025Q2 2025OCGNOcugen-$0.06-$0.05+$0.01-$0.05$0.35 million$1.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCBMGCellular Biomedicine GroupN/AN/AN/AN/AN/AEIGREiger BioPharmaceuticalsN/AN/AN/AN/AN/AIPHAInnate PharmaN/AN/AN/AN/AN/AIPHYFInnate PharmaN/AN/AN/AN/AN/AOCGNOcugenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBMGCellular Biomedicine GroupN/A0.470.47EIGREiger BioPharmaceuticalsN/A3.313.24IPHAInnate Pharma2.522.602.60IPHYFInnate PharmaN/A2.602.60OCGNOcugen9.181.831.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBMGCellular Biomedicine Group21.98%EIGREiger BioPharmaceuticals62.46%IPHAInnate Pharma0.16%IPHYFInnate PharmaN/AOCGNOcugen10.27%Insider OwnershipCompanyInsider OwnershipCBMGCellular Biomedicine Group8.50%EIGREiger BioPharmaceuticals4.22%IPHAInnate Pharma31.89%IPHYFInnate Pharma31.89%OCGNOcugen4.29%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCBMGCellular Biomedicine Group21719.48 millionN/AOptionableEIGREiger BioPharmaceuticals561.48 million1.42 millionOptionableIPHAInnate Pharma22092.18 million62.79 millionNot OptionableIPHYFInnate Pharma17983.83 million57.10 millionNot OptionableOCGNOcugen80292.30 million279.77 millionOptionableCBMG, EIGR, OCGN, IPHYF, and IPHA HeadlinesRecent News About These CompaniesOcugen executes licensing agreement with Kwangdong PharmaceuticalSeptember 15 at 11:08 AM | msn.comOcugen, Inc. Announces Licensing Agreement with Kwangdong Pharmaceutical for OCU400, Potentially Worth Up to $187.5 MillionSeptember 15 at 6:11 AM | quiverquant.comQOcugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in KoreaSeptember 15 at 6:03 AM | globenewswire.comNuveen LLC Takes Position in Ocugen, Inc. $OCGNSeptember 7, 2025 | marketbeat.comOcugen CEO to Speak at Investor Conferences in New York and MunichSeptember 6, 2025 | msn.comOcugen Enters Subscription Agreement with Carisma TherapeuticsSeptember 5, 2025 | tipranks.comCarisma Therapeutics stock soars after merger agreement with OcugenSeptember 3, 2025 | au.investing.comOcugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025September 2, 2025 | finance.yahoo.comOcugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025September 2, 2025 | globenewswire.comGMT Capital Corp Grows Position in Ocugen, Inc. $OCGNSeptember 1, 2025 | marketbeat.comOcugen (NASDAQ:OCGN) Stock Price Up 3% - Here's WhyAugust 27, 2025 | marketbeat.comOcugen (OCGN) Upgraded to Buy: Here's What You Should KnowAugust 26, 2025 | zacks.comOcugen IncAugust 25, 2025 | edition.cnn.comOcugen reports EMA positive advice for acceptability of OCU410STAugust 13, 2025 | msn.comOcugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to ...August 13, 2025 | bakersfield.comBOcugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt DiseaseAugust 13, 2025 | globenewswire.comOcugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and WarrantsAugust 12, 2025 | manilatimes.netMOcugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and WarrantsAugust 12, 2025 | globenewswire.comOcugen, Inc. Announces $20 Million Securities Purchase Agreement with Janus Henderson InvestorsAugust 8, 2025 | quiverquant.comQOcugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and WarrantsAugust 8, 2025 | globenewswire.com3OCGN : Demystifying Ocugen: Insights From 5 Analyst ReviewsAugust 4, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCBMG, EIGR, OCGN, IPHYF, and IPHA Company DescriptionsCellular Biomedicine Group NASDAQ:CBMGCellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.Eiger BioPharmaceuticals NASDAQ:EIGREiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.Innate Pharma NASDAQ:IPHA$2.06 +0.07 (+3.25%) Closing price 09/15/2025 03:57 PM EasternExtended Trading$2.07 +0.00 (+0.24%) As of 09/15/2025 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Innate Pharma OTCMKTS:IPHYF$2.00 +0.38 (+23.46%) As of 09/12/2025 01:55 PM EasternInnate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Ocugen NASDAQ:OCGN$1.20 +0.13 (+12.15%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$1.18 -0.02 (-1.33%) As of 09/15/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
